Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease
Transcranial pulse stimulation is a promising CE-marked noninvasive ultrasound neuromodulation therapy that can improve cognitive function and depressive symptoms in Alzheimer's disease patients, particularly those under 70 years of age, with an excellent safety profile and minimal adverse events. 1
What is TPS?
TPS is an ultrasound-based brain stimulation technique that delivers single, ultrashort ultrasound pulses to targeted brain regions. Unlike focused ultrasound techniques, TPS uses discrete pulse delivery (typically 6000 pulses per session at 0.20 mJ/mm², 5 Hz frequency) to modulate cortical excitability, induce neuroplasticity, and increase functional connectivity within memory networks 2. The technology has CE marking for Alzheimer's disease treatment in Europe 3.
Treatment Protocol
Standard Initial Protocol
- 6 sessions over 2 weeks (baseline treatment cycle)
- 6000 pulses per session
- Energy density: 0.20 mJ/mm²
- Frequency: 5 Hz
- Target areas: Frontoparietal brain regions using MRI-guided neuronavigation 1
Long-term Maintenance
For sustained benefit, monthly booster sessions (6000 pulses each) following the initial 2-week cycle show feasibility for maintaining cognitive stability over 12 months 4.
Targeting Approach
The most recent evidence suggests a multifocal stimulation approach (F-TOP2) targeting multiple cognitive domains rather than single-region stimulation, particularly focusing on:
- Dorsolateral prefrontal cortex (DLPFC)
- Hippocampus and parahippocampal cortex
- Precuneus
- Parietal cortex regions 4, 2
Critical caveat: MRI-guided neuronavigation is essential for precise targeting, as cortical atrophy in AD patients affects optimal stimulation delivery 5.
Efficacy
Cognitive Outcomes
The largest randomized controlled trial (n=60) demonstrated:
- Age-dependent response: Patients ≤70 years showed significant improvement in CERAD total scores (mean increase of 3.91 points at 3 months post-treatment vs. -1.83 for sham, P=.005) 1
- Older patients (>70 years): Mixed results, with some individual responders but no significant group effect 1
A systematic review of 99 AD patients across 5 studies confirmed significant improvements in:
- CERAD test battery scores
- ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive)
- MMSE and MoCA scores 6
Neuroimaging Evidence
TPS increases functional connectivity and activation in memory networks:
- Upregulated functional connectivity in hippocampus, parahippocampal cortex, precuneus, and parietal cortex
- Enhanced cortical activity in bilateral hippocampus
- Increased activation in the dorsal attention network 1, 2
Depressive Symptoms
Significant reduction in depressive symptoms (BDI-II scores decreased from 7.27 to 5.27 at 3 months, P=.008) in per-protocol analysis 1. This effect was consistent across multiple studies using ADAS-affective and Geriatric Depression Scale 6.
Disease Stabilization
Higher rates of "responders" (disease stabilization) compared to natural progression, with effects lasting up to 3 months post-treatment 2, 7.
Safety Profile
TPS demonstrates an excellent safety profile with medium risk classification for tissue overheating 5:
Common Adverse Events (all reversible, <1 day duration):
- Mild focal pain or scalp discomfort
- Transient headache
- Jaw pain
- Nausea
- Drowsiness
- Worsening mood (transient) 6, 4
Important Safety Data:
- No serious adverse events or major complications reported across all studies 6, 2
- No amyloid-related imaging abnormalities (ARIA) detected 7
- Adverse events occurred in <1% of stimulation sessions 4
- No major neuropathologic changes on detailed neuroradiologic assessments 1
- Silent operation with potential warmth sensation during treatment 5
Safety consideration: Careful patient selection and monitoring are advised, particularly in patients with underlying medical conditions where systemic behavioral or vigilance changes may occur 4.
Contraindications
While specific absolute contraindications are not explicitly detailed in the current evidence, the following warrant caution based on the mechanism and safety profile:
Relative Contraindications (inferred from ultrasound neuromodulation principles):
- Active intracranial pathology beyond AD (tumors, acute hemorrhage)
- Skull defects or cranial implants that may alter acoustic transmission
- Severe cardiovascular instability
- Patients unable to tolerate the procedure or provide informed consent
Critical gap: The current literature lacks comprehensive contraindication lists, requiring clinician judgment based on general ultrasound neuromodulation principles 3, 2.
Clinical Implementation Considerations
Patient Selection
Prioritize patients ≤70 years of age for optimal cognitive benefit, though individual older patients may still respond 1. The heterogeneous response pattern (individual trajectory range -0.053 to +0.336) suggests that response monitoring is essential 8.
Personalization Requirements
According to the most recent guidelines, structural MRI-based neuronavigation should be prioritized to account for cortical thinning and target functional networks like the default mode network 5. The significant brain atrophy in AD patients requires individualized targeting to ensure adequate field delivery 5.
Integration with Standard Care
TPS should be used as an add-on therapy to state-of-the-art AD treatment (acetylcholinesterase inhibitors, memantine), not as monotherapy 1, 6. The evidence suggests potential synergistic effects when combined with cognitive training, though optimal timing and integration protocols require further study 5.
Monitoring Response
Use validated neuropsychological assessments at baseline, 1 week, 1 month, and 3 months post-treatment:
- CERAD total score (primary outcome)
- MMSE and MoCA
- BDI-II for mood symptoms 1
Emerging approach: Connected-speech digital biomarkers show promise for scalable longitudinal monitoring of treatment response 8.
Evidence Limitations
Important caveats:
- Most studies lack sham controls or have small sample sizes 6
- Long-term effects beyond 12 months remain unexplored 4
- The single large RCT (n=60) showed no significant overall effect in intention-to-treat analysis, with benefits only in age-stratified subgroup analysis 1
- Optimal stimulation parameters, targeting strategies, and treatment schedules require further refinement 9
- A recent meta-analysis comparing focused TPS with unfocused LIPUS suggests unfocused approaches may have larger effect sizes (SMD=0.73 vs. 0.17), though this requires validation 7
Current status: Multiple randomized controlled trials are ongoing, and a living systematic review protocol has been established to continuously synthesize emerging evidence 9.